Market Overview

Teva Phase III Data for QNASL Demonstrate Efficacy Profile in Pediatric Patients with Seasonal Allergic Rhinitis

Teva Pharmaceutical (NASDAQ: TEVA) announced today additional data from
the Phase III clinical program for QNASL® (beclomethasone
dipropionate) Nasal Aerosol, highlighting the drug's efficacy profile in
treating children (ages 6-11) with nasal symptoms of seasonal allergic
rhinitis (SAR). QNASL® is a nonaqueous, “dry” nasal aerosol
corticosteroid currently approved for the treatment of nasal symptoms
associated with SAR and perennial allergic rhinitis (PAR) in patients
aged 12 years and older. The data are being presented at the 2012
Annual Meeting of the American College of Allergy, Asthma and Immunology
(ACAAI) in Anaheim, CA. Additional data also presented at the ACAAI
meeting reinforce the long-term ocular safety profile of QNASL®
and the functionality and reliability of the device.

See full press release

Posted-In: News Guidance Management Global

 

Related Articles (TEVA)

Around the Web, We're Loving...

Get Benzinga's Newsletters